Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.4K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.4K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.6K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

10.9K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
10.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher Cumulative Cytarabine Consolidation Improves Survival in Older Adults with Acute Myeloid Leukemia.

Cancers·2026
Same author

Suicidal Ideation Experienced by Long-Term Survivors of Blood or Marrow Transplantation: A Blood or Marrow Transplant Survivor Study Report.

Transplantation and cellular therapy·2026
Same author

Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation.

Blood advances·2026
Same author

Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS.

Blood advances·2026
Same author

Intestinal low-abundant bacteria drive MyD88/Trif-dependent CD8<sup>+</sup> T cell exhaustion in chronic myeloid leukemia.

Cell reports·2025
Same author

Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia.

Leukemia & lymphoma·2025
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
Same journal

Is low a go for pediatric AML?

Blood·2026
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K

Leukemia cells make ruthless competitors.

Ravi Bhatia1

  • 1CITY OF HOPE NATIONAL MEDICAL CENTER.

Blood
|November 8, 2014
PubMed
Summary
This summary is machine-generated.

Leukemia cells secrete factors that harm normal blood cell production. These leukemia-secreted factors damage and suppress the development of healthy hematopoietic stem cells.

More Related Videos

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

884

Related Experiment Videos

Last Updated: Apr 21, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.1K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

884

Area of Science:

  • Hematology
  • Cancer Biology
  • Stem Cell Biology

Background:

  • Normal hematopoiesis is crucial for maintaining blood cell populations.
  • Leukemia is characterized by uncontrolled proliferation of malignant hematopoietic cells.
  • The interaction between leukemia cells and the bone marrow microenvironment is complex.

Purpose of the Study:

  • To investigate the role of factors secreted by leukemia cells.
  • To determine how these secreted factors impact normal hematopoiesis.
  • To elucidate the mechanisms of leukemia-induced suppression of blood cell formation.

Main Methods:

  • Analysis of factors secreted by various leukemia cell lines.
  • Co-culture experiments with leukemia cells and normal hematopoietic stem and progenitor cells.
  • Assessment of hematopoietic stem cell function and differentiation in vitro and in vivo.

Main Results:

  • Identification of specific secreted factors from leukemia cells.
  • Demonstration that these factors directly inhibit normal hematopoietic stem cell proliferation and differentiation.
  • Evidence of impaired in vivo hematopoiesis in the presence of leukemia-secreted factors.

Conclusions:

  • Factors secreted by leukemia cells play a significant role in damaging and suppressing normal hematopoiesis.
  • Targeting these leukemia-secreted factors may offer a therapeutic strategy to restore normal blood cell production in leukemia patients.